Managing CLL Patients In 2018: Updates From The Recent ASH Congress
EHA Learning Center, Delivered by Janssen, 233813
Interpreting ASH 2017 updates for your daily clinical practice a roundtable discussion on MM
EHA Learning Center, Delivered by Janssen, 233812
Thrombosis The basics
EHA Learning Center, Roger Schutgens, 233293
A Paradigm Shift: Emerging Therapies in Flt3-Positive AML
EHA Learning Center, Delivered by Novartis, 224083
Amyloidosis: The rapidly changing face of diagnosis and therapy in AL amyloidosis
EHA Learning Center, Giampaolo Merlini, 219242
Treating Thalassemia: Thinking 'out of the box'
EHA Learning Center, Stefano Rivella, 219243
Normal and leukemic hematopoiesis in the bone marrow. Metabolic regulation in a dynamic environment
EHA Learning Center, Tsvee Lapidot, 219244
From epidemiology to treatment decisions (the role of T cell registries)
EHA Learning Center, Massimo Federico, 219234
PTCL: Evidence for subtype specific treatment approaches?
EHA Learning Center, F D'Amore, 219235
NK/T cell lymphoma: Novel insights, novel therapies?
EHA Learning Center, Won Seog Kim, 219236
HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY
EHA Learning Center, Lydia Scarfo, 219219
RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS
EHA Learning Center, Jong Wook Lee, 219221
THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB
EHA Learning Center, Rocco Piazza, 219222
CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Steffen Boettcher, 219223
ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY
EHA Learning Center, Meletios A Dimopoulos, 219224
MAPPING THE THREE-DIMENSIONAL GENOME DYNAMICS IN NORMAL AND NEOPLASTIC B CELLS
EHA Learning Center, Iñaki Martin-Subero, 219220
Mechanisms underlying oncogenic transcription factors in ALL
EHA Learning Center, Jan Cools, 219226
Novel genetic subgroups in acute lymphoblastic leukemia
EHA Learning Center, Christine Harrison, 219227
Single cell genomics in CML
EHA Learning Center, Adam Mead, 219230
Immune targeting of CML to improve treatment outcome
EHA Learning Center, Andreas Burchert, 219231
TFR treatment goal for all CML patients
EHA Learning Center, Delphine Rea, 219232
Future prospects for the treatment of hemophilia: A global perspective
EHA Learning Center, David Lillicrap, 219238
Monoclonal antibody-based therapies
EHA Learning Center, Midori Shima, 219239
Modified FVIII and FIX recombinant products
EHA Learning Center, Elena Santagostino, 219240
What are the treatment goals and optimal endpoints in RRMM
EHA Learning Center, Thierry Facon, 219202
How I manage extramedullary disease and plasma cell leukemia
EHA Learning Center, María-Victoria Mateos, 219203
Precision hematology: Implementing genomic profiling at national level
EHA Learning Center, Richard Rosenquist, 219209
Towards a molecular classification of Philadelphia- negative myeloproliferative neoplasms
EHA Learning Center, Radek Skoda, 219210
Molecular characterization as a basis for novel treatment paradigms in AML
EHA Learning Center, Hartmut Döhner, 219211
Assessing MRD in multiple myeloma
EHA Learning Center, Hervé Avet-Loiseau, 219212
New immunomodulators - New infectious diseases mind set?
EHA Learning Center, Sibylle Mellinghoff, 219214
Aspergillus resistance: Time to change the antifungal approach?
EHA Learning Center, Katrien Lagrou, 219215
One size does not fit all: Improving outcomes with personalized infection management?
EHA Learning Center, Martin Hönigl, 219216
Microenvironment in MPN
EHA Learning Center, Simon Mendez-Ferrer, 219198
Inflammation and anti-inflammatory approaches in MPN
EHA Learning Center, Steffen Koschmieder, 219199
Stem cell transplantation for myelofibrosis
EHA Learning Center, Nicolaus Kröger, 219200
Which are the preferred treatment combinations and sequence(s): In the transplant eligible / In the elderly
EHA Learning Center, Hartmut Goldschmidt, 219201
Biology of secondary leukemia
EHA Learning Center, Timothy Graubert, 219205
Impact of underlying disease on secondary leukemia
EHA Learning Center, Lene Sofie Granfeldt Østgård, 219206
Prognostic factors and treatment options in secondary leukemia
EHA Learning Center, Maria Teresa Voso, 219207
Bispecific antibodies for ALL
EHA Learning Center, Christina Peters, 219185
CART cells
EHA Learning Center, Franco Locatelli, 219186
Using patient-reported outcomes to improve toxicity assessment
EHA Learning Center, Fabio Efficace, 219188
Toxicity in hematologic malignancies: Considerations in bone marrow transplant, survivors and real world hematology patients
EHA Learning Center, John Gribben, 219189
Time trends in incidence rates of venous thrombosis
EHA Learning Center, Sigrid Braekkan, 219191
Future challenges in prevention and treatment of venous thrombosis
EHA Learning Center, John-Bjarne Hansen, 219192
Non-intensive treatment strategies in AML
EHA Learning Center, Gert Ossenkoppele, 219195
Intensive chemotherapy regimens in acute myeloide leukemia
EHA Learning Center, Je-Hwan Lee, 219196
The imperative for change in adverse event reporting in hematologic malignancies
EHA Learning Center, Gita Thanarajasingam, 219187
Jean Bernard Lifetime Achievement Award: Lecture
EHA Learning Center, Charolotte Niemeyer, 219180
José Carreras Award lecture: Research challenges and therapeutic perspectives in APL
EHA Learning Center, Francesco Lo Coco, 219182
Autoimmunity checkpoints as therapeutic targets in B-cell malignancies
EHA Learning Center, Markus Müschen, 219183
CAR T cell therapies for cancer
EHA Learning Center, Carl June, 219172
Molecular profiling in myeloma
EHA Learning Center, Faith E. Davies, 219161
Use of Patient Reported Outcomes (PRO) in hematology: Does it matter?
EHA Learning Center, Ton Hagenbeek, 219174
Regulatory authority guidelines for development and use of PRO instruments
EHA Learning Center, Tatiana Ionova, 219175
Genetics of classical Hodgkin Lymphoma (cHL)
EHA Learning Center, Enrico Tiacci, 219158
Optimization of the first line treatment in HD
EHA Learning Center, Pauline Brice, 219159
New strategies for relapsed/refractory Hodgkin lymphoma
EHA Learning Center, John Kuruvilla, 219160
Immunotherapy in myeloma: Why, when and how?
EHA Learning Center, Niels Van de Donk, 219162
Inherited predisposition to MDS/AML
EHA Learning Center, Jude Fitzgibbon, 219166
Optimal sequencing in the management of relapsed/refractory myeloma patients
EHA Learning Center, Philippe Moreau, 219163
Recent developments in immunotherapy in AML
EHA Learning Center, Marion Subklewe, 219167
Epigenetic therapy and beyond in AML
EHA Learning Center, Andrew Wei, 219168
PROs in solid tumours and hematological malignancies: How different are they?
EHA Learning Center, Pushpendra Goswami, 219176
Pathogenesis of cancer-associated thrombosis
EHA Learning Center, Nigel Mackman, 219396
Clinical prediction scores for venous thromboembolism in patients with a hematological malignancy
EHA Learning Center, Nick van Es, 219397
Cancer-associated thrombosis - Which lessons for the hematologist?
EHA Learning Center, Simon Noble, 219398
Clinical prediction scores for venous thromboembolism in patients with a hematological malignancy
EHA Learning Center, Nick van Es, 233285
Cancer-associated thrombosis - Which lessons for the hematologist?
EHA Learning Center, Simon Noble, 233286
Platelets and their ability to affect innate and adaptive immunity
EHA Learning Center, John Semple, 219155
Inherited platelet disorders caused by thrombopoietin mutations
EHA Learning Center, Federica Melazzini, 219156
Pathogenesis of CLL: the view from the lymph node
EHA Learning Center, Adrian Wiestner, 219093
Translating genetic and epigenetic knowledge into clinical utility
EHA Learning Center, Richard Rosenquist, 219094
Current role of chemotherapy free drug combinations for chronic lymphocytic leukemia
EHA Learning Center, Michael Hallek, 219095
Deregulation of cell signaling in marginal zone lymphoma
EHA Learning Center, Ming Qing Du, 219139
Marginal zone lymphoma: Differentiation among pathologically challenging entities
EHA Learning Center, Maurilio Ponzoni, 219140
From antibiotics to ibrutinib: An array of treatment modalities
EHA Learning Center, Catherine Thieblemont, 219141
Methods to detect minimal residual disease
EHA Learning Center, Torsten Haferlach, 219143
Clinical implications of minimal residual disease
EHA Learning Center, Jan Cornelissen, 219144
Preventing relapse of transplant
EHA Learning Center, Charles Craddock, 219145
Iron-sulfur protein biogenesis in health and disease
EHA Learning Center, Roland Lill, 219147
Congenital sideroblastic anemia: Iron and heme lost in mitochondrial translation
EHA Learning Center, Mark Fleming, 219148
Potential perils of iron supplementation in low income countries
EHA Learning Center, Andrew Prentice, 219149
Clinical and laboratory evaluation of acute blood loss and hemorrhagic shock
EHA Learning Center, Augusto B Federici, 219150
Update on the pathophysiology and management of acute trauma hemorrhage and trauma-induced coagulopathy
EHA Learning Center, Marc Maegele, 219151
Transfusion in patients with acute major blood loss: Evidence when, for whom and what products are best
EHA Learning Center, JJ Zwaginga, 219152
RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
EHA Learning Center, Franck Morschhauser, 215924
MPN CALR MUTANTS PROMOTE CELL-SURFACE LOCALIZATION OF TPOR WHICH IS OBLIGATORY FOR ONCOGENESIS: NOVEL THERAPEUTIC AVENUES AND RESCUE OF CONGENITAL THROMBOCYTOPENIA TPOR MUTANTS
EHA Learning Center, Christian Pecquet, 215926
CHRONIC RED BLOOD CELL TRANSFUSIONS IMPAIR THE INNATE IMMUNE RESPONSE TO INFECTIOUS CUES BY SHAPING MACROPHAGES TOWARDS AN ANTI-INFLAMMATORY FUNCTIONAL PHENOTYPE.
EHA Learning Center, Francesca Vinchi, 215928
OVERALL SURVIVAL BENEFIT OF OBINUTUZUMAB OVER RITUXIMAB WHEN COMBINED WITH CHLORAMBUCIL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMORBIDITIES: FINAL SURVIVAL ANALYSIS OF THE CLL11 STUDY
EHA Learning Center, Valentin Goede, 215923
RIBOSOMAL LESIONS PROMOTE ONCOGENIC MUTAGENESIS
EHA Learning Center, Sergey Sulima, 215927
FIRST-IN-HUMAN CLL1-CD33 COMPOUND CAR T CELLS AS A TWO-PRONGED APPROACH FOR THE TREATMENT OF REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Fang Liu, 215925
Perspectives with CAR-T for resistant ALL and beyond
EHA Learning Center, Sara Ghorashian, 219119
Designing clinical scale production of iPSC-derived platelets by a novel flow concept
EHA Learning Center, Koji Eto, 219123
Epigenetic inhibitors in hematological malignancies
EHA Learning Center, Brian Huntly, 219125
Inhibitors of isocitrate dehydrogenase in the treatment of acute myeloid leukemia
EHA Learning Center, Eytan Stein, 219126
Blood transfusion in developing countries: The case of Malawi and other African countries
EHA Learning Center, Brindon M'baya, 219128
Resolving hematopoiesis by fate mapping and polylox barcoding
EHA Learning Center, Hans-Reimer Rodewald, 219122
How to test and transfuse blood products in sub-Saharan Africa
EHA Learning Center, Jean Pierre Allain, 219129
David Grimwade Award Lecture: Precision medicine for blood cancers through knowledge banks
EHA Learning Center, Peter Campbell, 219116
Award ceremony: Presentation Young EHA Best abstracts
EHA Learning Center, Martina Muckenthaler, 219479
Opening Ceremony: Chair
EHA Learning Center, Martina Muckenthaler, 219114
Award ceremony
EHA Learning Center, Ruud Delwel, 219115
Award ceremony: Education and mentoring awards
EHA Learning Center, Pieter Sonneveld, 219480
Opening Ceremony: Chair
EHA Learning Center, Pieter Sonneveld, 219113
Blood transfustion in patients with sickle cell disease
EHA Learning Center, Karina Yazdanbakhsh, 219112
Immune development during fetal life and beyond, in health and disease
EHA Learning Center, Raz Somech, 219097
Update on congenital neutropenia
EHA Learning Center, Karl Welte, 219098
Evolving gene therapy for primary immunodeficiency
EHA Learning Center, Adrian Thrasher, 219099
Morphology of multiple myeloma, a patchy disease
EHA Learning Center, Gina Zini, 219101
Flow cytometry for Minimal/Measurable Residual Disease Detection (MRD) in Chronic Lymphocytic Leukaemia (CLL)
EHA Learning Center, Andy Rawstron, 219103
Introduction: Technical innovations in MRD measurements
EHA Learning Center, Jaques J. M. van Dongen, 219105
Droplet digital (dd) PCR for improved MRD measurements
EHA Learning Center, daniela drandi, 219106
High throughput flow cytometry for combined MRD measurements and immune monitoring
EHA Learning Center, Alberto Orfao, 219107
Multiple roles of LMWH in managing cancer-associated thrombosis
EHA Learning Center, Stephan Schneider, 219109
Preventing (recurrent) thrombosis without bleeding
EHA Learning Center, Harry Büller, 219111
Managing anti-thrombotic therapy in thrombocytopenic cancer patients: a double edged sword
EHA Learning Center, Avi Leader, 219110
Next generation sequencing (NGS) for MRD detection in acute lymphoblastic leukemia
EHA Learning Center, Jan Trka, 219419
Metabolic defects of the red blood cell
EHA Learning Center, R van Wijk, 219089
Genetics and genomics of erythrocyte membrane defects / Structural defects in RBCs
EHA Learning Center, Patrick Gallagher, 219090
Anemia in the elderly
EHA Learning Center, Domenico Girelli, 219091
Prediction versus empirical discovery: Lessons learned from the lymphoma neoantigen hunt
EHA Learning Center, Joshua Elias, 219073
Efficacy, safety and accessibility to CAR-T therapy for lymphomas
EHA Learning Center, Peter Borchmann, 219075
The hematopoietic niche in MDS: from concept to therapeutic target
EHA Learning Center, Marc Raaijmakers, 219077
Molecular genetics in clinical decision making
EHA Learning Center, Mario Cazzola, 219078
New treatment options
EHA Learning Center, Uwe Platzbecker, 219079
The role of the spleen in ITP
EHA Learning Center, James Bussel, 219081
The spleen in myeloproliferative neoplasms
EHA Learning Center, Pierre Buffet, 219082
The spleen in sickle cell disease
EHA Learning Center, Valentine Brousse, 219083
Regulation of gene expression in hematopoiesis
EHA Learning Center, Douglas Higgs, 219085
Clinical trials in hemoglobinopathies
EHA Learning Center, Miguel Abboud, 219087
Epidemiology in sickle cell disease - Lessons learned from a multinational cohort in sub-Saharan Africa
EHA Learning Center, brigitte ranque, 219086
TLS risk assessment with CLL therapies
EHA Learning Center, John Gribben, 209967
TLS prophylaxis and monitoring
EHA Learning Center, John Seymour, 209966
Clinical management of TLS
EHA Learning Center, Barbara Eichhorst, 209965
A challenging course through a difficult landscape
EHA Learning Center, Delivered by Janssen, 205759
Emerging treatment goals in chronic myeloid lymphoma
EHA Learning Center, Delivered by Novartis, 202870
HME FORUM Optimizing Outcomes For Patients With CLL
EHA Learning Center, Delivered by Janssen, 202871
HME FORUM The Clinical Implications of Our Improved Understanding Of CLL Biology
EHA Learning Center, Delivered by Janssen, 202872
Molecular pathology of Hodgkin´s lymphoma and prognostic implications
EHA Learning Center, Randy Gascoyne, 145397
The role of clinical prognostic factors in the PET era
EHA Learning Center, Laurie Sehn, 145398
Current approaches in the treatment of HL
EHA Learning Center, Massimo Federico, 145399
Radiotherapy in Hodgkin's Lymphoma: which dose and for whom
EHA Learning Center, Andreas Engert, 145400
New drugs in the treatment of relapsed / refractory Hodgkin's Lymphoma
EHA Learning Center, Anas Younes, 145401
Role of auto and allografts in Hodgkin lymphoma
EHA Learning Center, Anna Sureda, 145403
Late Effects of Hodgkin Lymphoma Treatment: Implications for Management of Contemporary Patients
EHA Learning Center, Simonetta Viviani, 145404
New treatment approaches in Hodgkin lymphoma in 2016
EHA Learning Center, Igor Aurer, 145402
Treatment of Patients With Myelofibrosis and Uncontrolled Polycythemia Vera
EHA Learning Center, Delivered by Novartis, 193789
ITP and AA: Our current understanding and what the future might hold
EHA Learning Center, Delivered by Novartis, 192923
From biology to targeted therapies in chronic lymphocytic leukemia
EHA Learning Center, Stephan Stilgenbauer, 184561
Hemophilia Treatment: Navigating Speed Bumps on the Innovation Highway
EHA Learning Center, Donna DiMichele, 184560
Managing CLL patients after BCR inhibitor failure
EHA Learning Center, Jeffrey Jones, 184553
Treatment Of Aggressive Lymphoma Focused On Elderly Patients
EHA Learning Center, Michael Pfreundschuh, 184545
New Treatment Approaches In Myeloma In 2017
EHA Learning Center, Jesús F. San-Miguel, 184549
Harnessing T cells for Immunotherapy of AML
EHA Learning Center, Marion Subklewe, 184556
New drugs for old? What is the role of B-cell receptor pathway inhibition in the front line therapy of CLL in 2017?
EHA Learning Center, Stephen Devereux, 184552
Relapsed aggressive lymphoma: Can we optimize the therapy
EHA Learning Center, Gilles Salles, 184544
Genetic Classification Of Myeloma For Prognostication And Treatment Selection
EHA Learning Center, Hervé Avet-Loiseau, 184548
First-line therapy for CLL in 2017
EHA Learning Center, Alessandra Tedeschi, 184551
Role of enhancers in the pathogenesis of AML
EHA Learning Center, Ruud Delwel, 184555
BONE MARROW SITES DIFFERENTLY IMPRINT DORMANCY AND CHEMORESISTANCE TO T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Françoise Pflumio, 183931
ARNT/HIF-1BETA LINKS POOR CLINICAL OUTCOME TO MICROENVIRONMENTAL HYPOXIA AND HIGH-RISK 1Q GAIN IN MULTIPLE MYELOMA
EHA Learning Center, Fengyan Jin, 183932
The Biological Basis Of Aggressive Lymphoma
EHA Learning Center, Elias Campo, 184543
Immunopathology of MM
EHA Learning Center, Nikhil Munshi, 184547
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS
EHA Learning Center, Gilles Salles, 183934
Prioritisation Therapies In CLL
EHA Learning Center, Clemens Wendtner, 184524
Indications For Transplantation In MDS
EHA Learning Center, Matteo Giovanni Della Porta, 184533
Red Cell Transfusion: When To Transfuse In Patients With Hematological Malignancies?
EHA Learning Center, Miguel Lozano Molero, 184537
Heat Shock Protein 70 (HSP70), one of the major key factors in Diamond-Blackfan anemia
EHA Learning Center, Lydie Da Costa, 184541
ELN-EHA-SWG on CML
EHA Learning Center, Jerry Radich, 184529
Prognostic Factors In CLL: When, Which And How?
EHA Learning Center, Sarka Pospisilova, 184523
ELN-EHA-SWG on CML
EHA Learning Center, Daniela Krause, 184528
Immune microenvironment in the pathogenesis of MDS
EHA Learning Center, Shahram Kordasti, 184532
Challenges In Typing And Matching Strategies In Patients With Hematological Maligancies In The Era Of Immunotherapy
EHA Learning Center, Karen Vooght, 184536
Iron overload before, during and after bone marrow transplantation
EHA Learning Center, Emanuele Angelucci, 184539
ELN-EHA-SWG on CML
EHA Learning Center, Alois Gratwohl, 184527
Relevance Of Microenvironment In CLL
EHA Learning Center, Federico Caligaris-Cappio, 184522
ELN-EHA-SWG on CML
EHA Learning Center, Delphine Rea, 184526
Clonal Evolution In MDS
EHA Learning Center, Joop Jansen, 184531
Cell-derived Microvesicles And Microparticles In Blood Components: Consequences For Transfusion Recipients
EHA Learning Center, Thierry Burnouf, 184535
Transferrin and TfR1 in co-regulation of erythropoiesis and iron metabolism
EHA Learning Center, Yelena Ginzburg, 184540
NLPHL - A Forgotten Entity?
EHA Learning Center, Andreas Engert, 184498
Non substitutive therapies for haemophilia
EHA Learning Center, Michael Makris, 184501
Early Phase Clinical Trials In Children: The European Perspective
EHA Learning Center, Christian Michel Zwaan, 184504
How to present and how to get published: Personal perspective from the Blood Editor-in-chief
EHA Learning Center, Bob Löwenberg, 184507
Double Hit Lymphoma
EHA Learning Center, MED Chamuleau, 184497
Factor VIII based
EHA Learning Center, Flora Peyvandi, 184500
New drugs for children with hematological malignancies - The US perspective
EHA Learning Center, Peter Adamson, 184503
Introduction: Early Career Committee, Overview on Early Career Session 2 and the two Bite-size classes
EHA Learning Center, Verena I Gaidzik, 184506
Heterogeneity in the making of blood
EHA Learning Center, David Scadden, 184495
Jean Bernard Lifetime Achievement Award: Introduction
EHA Learning Center, Tony Green, 184492
AML Treatment Beyond 3+7
EHA Learning Center, Norbert Vey, 184474
Fertility preservation in pre-pubertal and adolescent males
EHA Learning Center, Rod Mitchell, 184479
Controversies in treating small clots in the leg and in the lung
EHA Learning Center, Sebastian Schellong, 184487
CRISPR/Cas9 genome editing, from mechanism to therapy
EHA Learning Center, Jacob Corn, 184491
Fertility Preservation In Female Patients
EHA Learning Center, Marie-Madeline Dolmans, 184478
Targeting Mutated FLT3
EHA Learning Center, Mark Levis, 184473
What patients expect from hematologists
EHA Learning Center, A Plate, 184477
Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism
EHA Learning Center, Menno Huisman, 184486
Towards clinical translation of targeted gene editing in human hematopoietic stem cells
EHA Learning Center, Luigi Naldini, 184490
Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism
EHA Learning Center, Menno Huisman, 233284
France-Belgium-Switzerland: The GRAALL Intergroup
EHA Learning Center, Hervé Dombret, 184481
Molecular Diagnostics In AML
EHA Learning Center, Lars Bullinger, 184472
The effects of chemotherapy and radiotherapy on reproduction
EHA Learning Center, William Hamish Wallace, 184476
Major results and future approaches of Italian ALL study groups
EHA Learning Center, Sabina Chiaretti, 184480
Cross-talk between inflammation and coagulation
EHA Learning Center, Thomas Renné, 184485
Circulating tumor DNA in Non-Hodgkin lymphoma: Clinical and future research applications
EHA Learning Center, Mark Roschewski, 184470
How to treat CML in 2017
EHA Learning Center, Andreas Hochhaus, 184454
GVL And GVHD Differences And Similarities
EHA Learning Center, Fred Falkenburg, 184458
Neurological complications of sickle cell disease
EHA Learning Center, Fenalla Kirkham, 184462
Rare bleeding disorders - Diagnosis and treatment
EHA Learning Center, Gili Kenet, 184466
Interim-PET as a valid biomarker for early response in malignant lymphoma; when to perform and how to assess
EHA Learning Center, Josee Zijlstra, 184469
Do we still need bone marrow biopsies?
EHA Learning Center, Tarec El-Galaly, 184468
Molecular work up and monitoring of CML patients
EHA Learning Center, NCP Cross, 184453
The Role Of Intestinal Flora In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
EHA Learning Center, Marcel van den Brink, 184457
Iron Chelation In Hemoglobinopathies
EHA Learning Center, Vip Viprakasit, 184461
Diagnosis and management of DIC and primary hyperfibrinolysis
EHA Learning Center, Alessandro Squizzato, 184465
Introduction EHA LyG
EHA Learning Center, Marie José Kersten, 184467
Novel approaches to eradicate CML stem cells
EHA Learning Center, Mhairi Copland, 184452
GvHD Prophylaxis And Treatment, New Modalities
EHA Learning Center, Robert Zeiser, 184456
Genome editing in hemoglobinopathies
EHA Learning Center, Mitch Weiss, 184460
Biological and clinical relevance of fibrin clot structure
EHA Learning Center, Nicola Mutch, 184464
TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP
EHA Learning Center, Peter Borchmann, 181437
REVERSIBLE PHARMACOLOGICAL TARGETING OF RHOA ALLOWS IMPROVED STORAGE, SURVIVAL AND HEMOSTATIC ACTIVITY OF PLATELETS IN VITRO AND IN VIVO, IN MICE AND IN PRIMATES.
EHA Learning Center, Shailaja Hegde, 181436
EXPOSURE TO INFECTION TRIGGERS PAX5 AND ETV6-RUNX1 CHILDHOOD BCP-ALL
EHA Learning Center, Julia Hauer, 181435
RE-CREATING HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN (HPFH) WITH CRISPR/CAS9 TO TREAT SICKLE CELL DISEASE (SCD) AND BETA-THALASSEMIA (BETA-THAL)
EHA Learning Center, Bill Lundberg, 181434
Myeloid malignancies
EHA Learning Center, Mario Cazzola, 184436
Novel Treatment Strategies In Waldenström's Macroglobulinemia
EHA Learning Center, Efstathios Kastritis, 184439
Risk Adapted Treatment Of CMML
EHA Learning Center, Eric Padron, 184445
Targeted next generation sequencing to improve diagnosis of rare anaemia
EHA Learning Center, Barnaby Clark, 184448
What's new in the 2016 WHO lymphoma classification?
EHA Learning Center, Steven Swerdlow, 184435
Molecular Biology Of Waldenström's Disease
EHA Learning Center, Steven Treon, 184438
Clinical Heterogeneity Of Ambiguous Lineage Leukemias: Search For Optimal Treatment Strategy
EHA Learning Center, Ondřej Hrusak, 184441
From Genetics To Epigenetics In Chronic Myelomonocytic Leukemia
EHA Learning Center, Eric Solary, 184444
Genetic Studies Of Human Erythropoiesis
EHA Learning Center, Vijay Sankaran, 184447
José Carreras Lecture: AML: The Evil side of gene regulation
EHA Learning Center, Ruud Delwel, 184433
Introduction José Carreras Award & Lecture
EHA Learning Center, Shai Izraeli, 184432
Presentation EHA - José Carreras young investigator award & EHA research grants
EHA Learning Center, Martina Muckenthaler, 184431
Opening address
EHA Learning Center, Tony Green, 184430
Updates in the frontline setting and relapse MM from IMW 2017: An expert roundtable discussion
EHA Learning Center, Delivered by Janssen, 183453
Is transplantation still needed in the era of immunotherapy?
EHA Learning Center, Anna Sureda, 184415
Harnessing T-cell mediated anti-leukemic effect: From unmanipulated donor T-cells to tumor-specific and  genetically modified T-cells
EHA Learning Center, Hans-Jochem Kolb, 184419
Immunosenescence: When And How To Vaccinate Older Patients With Malignant Hemopathies?
EHA Learning Center, Raphael Solana, 184422
RBC hydration defects
EHA Learning Center, Carlo Brugnara, 184429
Immune checkpoint inhibitors
EHA Learning Center, Anas Younes, 184414
Engineering NK cells for the treatment of hematologic malignancies
EHA Learning Center, Katy Rezvani, 184425
The long journey of donor search: From sibling to MUD to cord and haplo transplantation
EHA Learning Center, eliane Gluckman, 184418
Immunosenescence Or Why Are Older Patients More Sensitive To Malignancies?
EHA Learning Center, Tamas Fulop, 184421
Stomatocytosis and allied disorders
EHA Learning Center, Immacolata Andolfo, 184428
Microenvironment in lymphoma
EHA Learning Center, Georg Lenz, 184413
From dogs to humans... The 60 year long road of allogeneic stem cell transplantation
EHA Learning Center, Rainer Storb, 184417
Elderly task force in hematology: Chair
EHA Learning Center, Dominique Bron, 184420
Functional diversification of human NK cells
EHA Learning Center, Kalle Malmberg, 184424
RBC membrane transport in health and disease
EHA Learning Center, Giel Bosman, 184427
PEG Filgrastim in SCN
EHA Learning Center, Francesca Fioredda, 184410
Treatment of extranodal marginal zone B-cell lymphomas
EHA Learning Center, Markus Raderer, 184394
Emerging treatments for classical myeloproliferative neoplasms
EHA Learning Center, Claire Harrison, 184398
The 100.000 genomes project
EHA Learning Center, Willem Ouwehand, 184406
Although ALL is highly curable with conventional chemotherapy, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL, especially in adults.Immunotherapeutic approaches have significantly improved the outcome of R
EHA Learning Center, Jose Maria Ribera, 184402
Neutrophil extra cellular traps (NET)
EHA Learning Center, Jean Donadieu, 184409
Update on follicular lymphoma: Time beyond chemotherapy?
EHA Learning Center, Kai Hübel, 184393
Targeting specific mutations in MPN
EHA Learning Center, Ann Mullally, 184397
Immunotherapy of ALL from biology to the clinic and back
EHA Learning Center, Terry Fry, 184401
Syndromes predisposing to hematological malignancies
EHA Learning Center, Christian Kratz, 184405
Drivers of leukemogenesis in congenital neutropenias
EHA Learning Center, Karl Welte, 184408
Molecular profiling of indolent lymphoma
EHA Learning Center, Stefano Pileri, 184392
Molecular genetics in MPN
EHA Learning Center, Alessandro M. Vannucchi, 184396
Balance of efficacy vs toxicity in treatment of childhood ALL: Time for dose reductions?
EHA Learning Center, Ajay Vora, 184400
Diagnosis of inherited bone marrow failure and myelodysplastic syndromes
EHA Learning Center, Akiko Shimamura, 184404
Interpreting recent updates on AML and low risk MDS for daily clinical practice
EHA Learning Center, Delivered by Janssen, 183902
Management of CLL patients in the front-line setting
EHA Learning Center, Delivered by Janssen, 170239
HME ASCO and EHA
EHA Learning Center, Delivered by Janssen, 165716
Update on new agents in multiple myeloma – focus on monoclonal antibodies: An expert roundtable discussion
EHA Learning Center, Delivered by Janssen, 164424
Disease Background in acute myeloid leukemia
EHA Learning Center, Delivered by Novartis, 151203
Management strategies of in MCL and WM – a roundtable discussion
EHA Learning Center, Delivered by Janssen, 147234
Strategies to apply recent data in CLL and MCL into clinical practice
EHA Learning Center, Delivered by Janssen, 142525
Strategies to apply recent data in AML and MDS into clinical practice
EHA Learning Center, Delivered by Janssen, 137865
Strategies to apply recent data in multiple myeloma into clinical practice
EHA Learning Center, Delivered by Janssen, 137864
The role of direct oral anticoagulants in 2016
EHA Learning Center, Paul Alexander Kyrle, 137118
Causes and consequences of microRNA dysregulation in cancer
EHA Learning Center, Carlo M. Croce, 137117
Clonal evolution of MDS
EHA Learning Center, Benjamin Ebert, 137116
Do we really need new drugs for PV and ET? NO
EHA Learning Center, Carlos Besses, 137110
THE ANTI C1S COMPLEMENT ANTIBODY TNT009 INDUCES RAPID COMPLETE REMISSIONS OF ANAEMIA IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE
EHA Learning Center, Ulrich Jäger, 135348
Do we really need new drugs for PV and ET? YES
EHA Learning Center, Haifa Kathrin Al-Ali, 137109
PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
EHA Learning Center, Antonio Palumbo, 135347
Do we really need new diagnostic criteria for MPNs? NO
EHA Learning Center, Jean-Jacques Kiladjian, 137108
Platelets from HIV+ HAART-treated patients contain infectious virus and interact with macrophages
EHA Learning Center, Fernando Real, 135346
Do we really need new diagnostic criteria for MPNs? YES
EHA Learning Center, Tiziano Barbui, 137107
PLATELET TRANSFUSION IN CEREBRAL HAEMORRHAGE (PATCH): A RANDOMISED CONTROLLED TRIAL
EHA Learning Center, Maria Koopman, 135345
OVERALL SURVIVAL IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS RECEIVING INOTUZUMAB OZOGAMICIN VS STANDARD CARE IN THE PHASE 3 INO-VATE STUDY
EHA Learning Center, Hagop P Kantarjian, 135344
How to sequence novel agents in Myeloma
EHA Learning Center, Hartmut Goldschmidt, 137098
Challenges for red blood cell biomarker discovery through proteomics
EHA Learning Center, Monique Slijper, 137102
How will monoclonal antibodies change therapy
EHA Learning Center, Philippe Moreau, 137097
Hemolysis and its consequences
EHA Learning Center, Dominik Schaer, 137101
Minimal residual disease including imaging
EHA Learning Center, Bruno Paiva, 137096
Hypomethylating agents in MDS
EHA Learning Center, V Santini, 136673
Hypomethylating agents in MDS
EHA Learning Center, V Santini, 193786
Standard treatment for lower-risk MDS - Where do we stand?
EHA Learning Center, Eva Hellström- Lindberg, 193785
Standard treatment for lower-risk MDS - Where do we stand?
EHA Learning Center, Eva Hellström- Lindberg, 136672
Clinical implications of gene mutations in MDS
EHA Learning Center, Rafael Bejar, 136671
Progress in treatment of ALL in adults
EHA Learning Center, Nicola Gökbuget, 136670
New technologies for MRD in ALL- challenges and opportunities
EHA Learning Center, Jaques J. M. van Dongen, 136669
The role of non-coding DNA in the pathogenesis of T-ALL
EHA Learning Center, Marc Mansour, 136668
JAK inhibitors in MF and PV
EHA Learning Center, Haifa Kathrin Al-Ali, 136667
Mutations and their clinical implications
EHA Learning Center, Paola Guglielmelli, 136666
Role of CALR and its deregulation in MPN
EHA Learning Center, Thorsten Klampfl, 136665
Who should be transplanted in the molecular era?
EHA Learning Center, Richard Schlenk, 136664
Dissecting genetic and phenotypic heterogeneity to deliver personalized predictions in AML patients
EHA Learning Center, Elli Papaemmanuil, 136662
Targeting mutant IDH
EHA Learning Center, Eytan Stein, 136663
Management of MCL in the era of targeted drugs
EHA Learning Center, Tadeusz Robak, 136661
Risk-stratification therapy in MCL
EHA Learning Center, Emanuele Zucca, 136660
Predicting disease behavior in MM - Molecular risk factors and the road to stratified medicine
EHA Learning Center, Martin Kaiser, 137095
Sickle cell disease and red cell volume
EHA Learning Center, John Gibson, 137100
Molecular pathogenesis of MCL
EHA Learning Center, German Ott, 136659
Targeted genome editing in hematopoietic stem cells
EHA Learning Center, Luigi Naldini, 137089
Immune checkpoint blockade in lymphoma
EHA Learning Center, Philippe Armand, 137088
Jean Bernard Lifetime Achievement Award: Acceptance Speech - Iron, erythropoiesis and beyond
EHA Learning Center, Clara Camaschella, 137085
Patents and diagnostic testing: another marriage on the rocks or a(n) (un)wanted relationship?
EHA Learning Center, Sven Bostyn, 137078
Clones and subclones during ALL development
EHA Learning Center, Jan Trka, 137083
Patenting in diagnostics: Damned if you do, damned if you don't
EHA Learning Center, Eric Claassen, 137077
Oncogenetic heterogeneity of ALL cells
EHA Learning Center, Stephan Hunger, 137082
Q&A and Panel Discussion
EHA Learning Center, Session Speakers, 141696
The meaning of circulating plasma cells in myeloma patients
EHA Learning Center, Bruno Paiva, 137072
Symptoms and health-related quality of life issues considered important by patients with hematological malignancies: Patient perspective
EHA Learning Center, Roger Else, 137067
Multiple myeloma: Spatial genomic heterogeneity between focal lesions and random bone marrow
EHA Learning Center, Niels Weinhold, 137071
Challenges of assessing symptom burden in patients with hematological malignancies: Academic perspective
EHA Learning Center, Tatiana Ionova, 137066
Hemostatic management of bleeding in obstetrics and gynecology
EHA Learning Center, Claire Philipp, 136658
Genetic basis of rare inherited platelet disorders in the era of next-generation sequencing
EHA Learning Center, Kathleen Freson, 136657
Challenges of assessing symptoms for monitoring response to treatment in patients with ematological malignancies: Learning from best practice
EHA Learning Center, Jonathan Kell, 137065
B-cell maturation pathways and migration
EHA Learning Center, Alberto Orfao, 137070
Blood outgrowth endothelial cells in understanding von Willebrand disease
EHA Learning Center, Anna Randi, 136656
International Harmonization Group For Surveillance Of Late Effects Of Childhood Cancer
EHA Learning Center, Leontien Kremer, 136655
The spectrum of late effects after cancer, lessons from pediatric oncology, and the value of international collaboration
EHA Learning Center, Roderick Skinner, 136654
Deciphering genetic variation of early and late effects from childhood cancer therapies
EHA Learning Center, Bruce Carleton, 136653
Antiplatelet therapy in acute and chronic ischemic heart disease
EHA Learning Center, Freek Verheugt, 136652
Platelet reactivity testing: Is there a clinical relevance?
EHA Learning Center, Jolanta Siller Matula, 136651
Platelets and immunity
EHA Learning Center, Harald Langer, 136650
Treatment of HLH in adults
EHA Learning Center, Nancy Berliner, 136649
Malignancy associated HLH
EHA Learning Center, Milen Minkov, 136648
HLH: Variations in etiology, pathophysiology and manifestations
EHA Learning Center, Michael Jordan, 136647
The role of the blood film in diagnosing and managing red cell disorders
EHA Learning Center, Barbara Bain, 136646
Clinical trials and potential targets of therapy in sickle cell disease
EHA Learning Center, Bart Biemond, 136645
Anemia of chronic disease - New insights into its pathophysiology and therapy
EHA Learning Center, Guenter Weiss, 136644
GVHD prophylaxis with PTCy
EHA Learning Center, Leo Leonio, 136675
Recent advances in understanding the pathophysiology of GVHD
EHA Learning Center, Ron Chakraverty, 136674
AN OPEN-LABEL, RANDOMISED PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX
EHA Learning Center, Meletios A Dimopoulos, 135349
ETV6-RELATED THROMBOCYTOPENIA (ETV6-RT): CLINICAL AND PATHOGENETIC CHARACTERIZATION OF AN INHERITED THROMBOCYTOPENIA (IT) PREDISPOSING TO CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
EHA Learning Center, Federica Melazzini, 135181
PERSISTENCE OF DRIVER MUTATIONS DURING COMPLETE REMISSION ASSOCIATES WITH SHORTER SURVIVAL AND CONTRIBUTES TO THE INFERIOR OUTCOMES OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Maja Rothenberg-Thurley, 135179
STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL
EHA Learning Center, Johan Richter, 135178
Q&A and Panel Discussion
EHA Learning Center, Session Speakers, 141695
Infections in refugees
EHA Learning Center, Gerd Fätkenheuer, 137057
The hematological spectrum of GATA2 mutations
EHA Learning Center, Venetia Bigley, 137053
Sickle cell disease in Africa: Experience from Tanzania in clinical and genomic research
EHA Learning Center, Julie Makani, 137050
New diseases on the European horizon: Sickle cell disease and thalassemia in refugees
EHA Learning Center, Andreas Kulozik, 137056
Frequent medical problems in refugees
EHA Learning Center, Christine Chomienne, 137055
Thalassemias In South Asia
EHA Learning Center, Anuja Premawardhena, 137049
Genomic analysis of inherited bone marrow failure and myelodysplastic syndrome
EHA Learning Center, Ivo Touw, 137052
José Carreras lecture: Towards understanding the anemia of myelodysplastic syndromes
EHA Learning Center, Eva Hellström- Lindberg, 137047
EHA21 José Carreras award: Opening Ceremony
EHA Learning Center, Andreas Engert, 137046
EHA21 Opening Ceremony: President's speech
EHA Learning Center, Tony Green, 137042
EHA21 Opening Ceremony: SPC Chair speech
EHA Learning Center, Andreas Engert, 137043
Q&A and Panel Discussion
EHA Learning Center, Session Speakers, 141358
Antidotes for novel oral anticoagulants
EHA Learning Center, Jean Marie Connors, 137041
HTS for IG and TR repertoire studies in lymphoproliferative diseases
EHA Learning Center, Kostas Stamatopoulos, 137037
HTS for minimal residual disease in lymphoid malignancies
EHA Learning Center, Monika Brüggemann, 137036
When and how to test for heparin-induced thrombocytopenia (HIT) antibodies?
EHA Learning Center, Yves Gruel, 137040
Bioinformatic strategies for HTS data analysis
EHA Learning Center, Nikos DARZENTAS, 137035
Introduction: Strategies for HTS of IG-TR genes: Possibilities and limitations
EHA Learning Center, Anton Langerak, 137034
Genomics and NGS in thrombosis
EHA Learning Center, Pieter Reitsma, 137039
Drug induced immune thrombocytopenia
EHA Learning Center, Tamam Bakchoul, 137030
Inherited thrombocytopenias predisposing to hematological malignancies
EHA Learning Center, Hana Raslova, 137029
Predictors of bleeding in thrombocytopenic patients
EHA Learning Center, Paolo Gresele, 137028
Panel Discussion
EHA Learning Center, Session Speakers, 137627
New treatment approaches in Hodgkin lymphoma in 2016
EHA Learning Center, Igor Aurer, 136643
Risk adapted treatment of early stage HL
EHA Learning Center, Marc André, 136642
Pathogenesis of HL
EHA Learning Center, Ralf Küppers, 136641
Treatment of the elderly CLL patients
EHA Learning Center, Barbara Eichhorst, 136640
Prognostic and predictive factors in the era of new targeted therapies
EHA Learning Center, Davide Rossi, 136639
B-cell receptor structure and function in CLL
EHA Learning Center, Francesco Forconi, 136638
Evidence based transfusion medicine for coagulopathy in patients with CLD
EHA Learning Center, Pratima Chowdary, 136637
Transfusion management of coagulation abnormalities in CLD: From bench to bedside
EHA Learning Center, Armando Tripodi, 136636
Hemostasis and thrombosis in patients with liver disease
EHA Learning Center, Ton Lisman, 136635
Primary CNS Lymphoma
EHA Learning Center, Andres Jose Maria Ferreri, 136634
Histiocytic disorders of children and adults
EHA Learning Center, Maarten Egeler, 136633
Systemic Mastocytosis for the Hematologist
EHA Learning Center, Hanneke Kluin-Nelemans, 136632
Immunological predictors of successful treatment discontinuation
EHA Learning Center, Satu Mustjoki, 136631
What have we learned from stopping TKI treatment in CML?
EHA Learning Center, Susanne Saußele, 136630
Molecular architecture of MM
EHA Learning Center, Brian Walker, 136623
Pathophysiology and diagnosis of MM bone disease
EHA Learning Center, Evangelos Terpos, 136624
Smoldering MM
EHA Learning Center, Maria Victoria Mateos, 136625
NF-kappaB cooperating events in mature B cell derived malignancies
EHA Learning Center, Dinis Calado, 136626
Intravascular Large B-cell Lymphoma
EHA Learning Center, Maurilio Ponzoni, 136627
Primary cutaneous B-cell lymphomas
EHA Learning Center, Rein Willemze, 136628
Modeling CML blast crisis
EHA Learning Center, Brian Huntly, 136629
European Iron Academy 'IV Iron preparations and safety session'
EHA Learning Center, Delivered by Vifor, 134439
European Iron Academy Hematology and Oncology Break out session
EHA Learning Center, Delivered by Vifor, 134440
The Global Burden of anaemia and iron deficiency anaemia
EHA Learning Center, Delivered by Vifor, 134442
State of the art update on CLL: An expert roundtable discussion - 14 April 2015
EHA Learning Center, Delivered by Janssen, 134444
Roundtable discussion on CLL
EHA Learning Center, Delivered by Janssen, 134445
State of the art update on multiple myeloma
EHA Learning Center, Delivered by Janssen, 134446
Toolkit for Pathologists
EHA Learning Center, Delivered by Janssen, 132332
Tumor microenvironment: a rational therapeutic target for lymphomas
EHA Learning Center, John Gribben, 103669
ITP in the 21st Century
EHA Learning Center, Drew Provan, 103667
Tracking and targeting leukemic stem cells
EHA Learning Center, Ravi Majeti, 103668
Efficacy and safety of inotuzumab ozogamicin (INO) vs standard of care (SOC) in salvage 1 or 2 patients with acute lymphoblastic leukemia (ALL): An ongoing global phase 3 study
EHA Learning Center, Helen Thackray, 103387
Patient-reported outcomes (PROS) in persist-1: A randomized, multi-country phase III trial of the JAK2 inhibitor pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis
EHA Learning Center, Adam Mead, 103386
Non-coding RNA and hematopoietic system development
EHA Learning Center, Frank Speleman, 103656
Hematopoiesis: Normal and Reprogrammed
EHA Learning Center, Kateri Moore, 103650
Generation and expansion of HSCs by microRNAs
EHA Learning Center, Gerald de Haan, 103649
EHA20 José Carreras Award Young - Opening ceremony
EHA Learning Center, Martina Muckenthaler, 103636
The role of long non-coding RNAs in cancer
EHA Learning Center, Marta Montes, 103655
Assessment of intravenous ferric carboxymaltose versus oral iron sulphate in the management of preoperative anaemia: A prospective randomized controlled trial
EHA Learning Center, Alhossain Khalafallah, 103383
APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA
EHA Learning Center, Alan Burnett, 103381
Perioperative thromboprophylaxis in patients with bleeding disorders
EHA Learning Center, Cedric Hermans, 103574
Longer-acting agents for the treatment of bleeding disorders
EHA Learning Center, Johannes Oldenburg, 103573
Novel concepts for coagulation activation
EHA Learning Center, James Morrissey, 103572
The role of PET in the management of DLBCL
EHA Learning Center, Olivier CASASNOVAS, 103586
How does one work up an AML patient in the molecular era
EHA Learning Center, Torsten Haferlach, 103570
Epigenetic targeting of AML
EHA Learning Center, Ross L. Levine, 103569
DLBCL: How much do we need to know at diagnosis?
EHA Learning Center, Wolfram Klapper, 103585
Molecular classification of MDS
EHA Learning Center, Luca Malcovati, 103597
Modeling splice factor mutations
EHA Learning Center, Omar Abdel-Wahab, 103647
Molecular classification of MDS
EHA Learning Center, Luca Malcovati, 193781
Alternative splicing alterations in cancer
EHA Learning Center, Didier Auboeuf, 103646
MDS stem cell biology
EHA Learning Center, Petter Woll, 103596
Unraveling the molecular biology of normal karyotype AML
EHA Learning Center, George Vassiliou, 103568
MDS stem cell biology
EHA Learning Center, Petter Woll, 193779
Haematologica Celebration Session: Making blood: the niche in health and disease
EHA Learning Center, David Scadden, 103641
CAR-T Cells
EHA Learning Center, Carl June, 103664
Iron: a global issue in hematology
EHA Learning Center, Clara Camaschella, 103663
Jean Bernard Lifetime Achievement Award: Acceptance Speech
EHA Learning Center, Volker Diehl, 103671
Mycosis Fungoides: Diagnostic Considerations
EHA Learning Center, Patty Jansen, 103613
Novel Biological Insights In Primary Cutaneous T-cell Lymphomas Other Than Mycosis Fungoides
EHA Learning Center, Leticia Quintanilla-Martinez, 103612
Therapeutic principles in primary cutaneous T-cell lymphomas
EHA Learning Center, Emmanuella Guenova, 103614
AMR - A threat to modern medicine
EHA Learning Center, Sally Davies, 103674
RUNX1 and ETS abnormalities in T-ALL
EHA Learning Center, Vahid Asnafi, 103660
Gene Therapy
EHA Learning Center, Marina Cavazzana-Calvo, 103617
Chromothripsis in ALL - the chromosome 21 model
EHA Learning Center, Christine Harrison, 103659
Novel erythropoiesis stimulating agents in thalassemia
EHA Learning Center, John Porter, 103616
New treatments in SCD
EHA Learning Center, Lucia De Franceschi, 103618
Genome wide molecular signatures in acute leukemia
EHA Learning Center, Joost Martens, 103658
Signaling inhibitors: what is the next step?
EHA Learning Center, John Byrd, 103578
The CLL epigenome: biological and clinical insights
EHA Learning Center, Iñaki Martin-Subero, 103576
The genomic landscape of CLL: clinical implications
EHA Learning Center, Gianluca Gaidano, 103577
iPS from somatically mutated abnormalities
EHA Learning Center, Isabelle Plo, 103652
iPS modeling of severe congenital neutropenia
EHA Learning Center, Jose A. Cancelas, 103653
Management of acute pulmonary embolism
EHA Learning Center, Cecilia Becattini, 103630
New methodologies and monitoring tools for CML
EHA Learning Center, Simona Soverini, 103582
Towards culturing granulocytes: Lessons learned from in vitro culture of red blood cells
EHA Learning Center, Ash Toye, 103633
Thrombosis and innate immunity
EHA Learning Center, Bernd Engelmann, 103629
Biology of CML
EHA Learning Center, Danilo Perrotti, 103580
The Efficacy Of Granulocyte Transfusion Therapy
EHA Learning Center, Thomas Price, 103634
Coagulation and non-coagulation effects of thrombin
EHA Learning Center, Henri Spronk, 103628
Combination of gene transfer and forced Chromatin looping concurrently to decreases Sickle Cell Hemoglobin and Reactivates the Synthesis of Fetal Hemoglobin in patient cells
EHA Learning Center, Stefano Rivella, 103159
Analysis of new GFI1B variants in patiens with inherited bleeding and platelet disorders
EHA Learning Center, Anna Marneth, 103130
DNMT3A R882 mutations promote chemoresistance and therapeutic relapse through impaired DNA damage sensing
EHA Learning Center, Olga Guryanova, 103231
Recurrent MTORC1-activating RRAGC Mutations in Follicular Lymphoma
EHA Learning Center, Jessica Okosun, 103072
Eloquent-2: A phase 3, randomized, open-label study of lenalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma
EHA Learning Center, Meletios A Dimopoulos, 103089
EHA20 José Carreras Award: Opening ceremony
EHA Learning Center, David Grimwade, 103637
EHA20 Opening Ceremony: President's speech
EHA Learning Center, Christine Chomienne, 103635
Curing APL through therapy induced PML/RARA degradation
EHA Learning Center, Hugues de Thé, 103638
What Do We Know About Leukemic Events In Myeloproliferative Neoplasms?
EHA Learning Center, Jean-Jacques Kiladjian, 103602
Remaining issues in pediatric ALL
EHA Learning Center, Andre Baruchel, 103566
Haploidentical transplants: state of the art
EHA Learning Center, Ibrahim Yakoub-Agha, 103622
What did we learn from CALR mutations
EHA Learning Center, Heinz Gisslinger, 103601
T Replete or T-Deplete: which is better?
EHA Learning Center, Andrea Bacigalupo, 103621
Novel oncogenetic pathways in ALL
EHA Learning Center, Tariq Enver, 103564
How to select the best available HSC donor
EHA Learning Center, Jean-Marie Tiercy, 103620
Signaling alterations in MPNs
EHA Learning Center, Stefan N Constantinescu, 103600
New And Emerging Prognostic And Predictive Biomarkers In ALL
EHA Learning Center, Anthony Moorman, 103565
Management of relapsed/refractory MM
EHA Learning Center, Pieter Sonneveld, 103594
New treatments for neonatal alloimmune thrombocytopenia
EHA Learning Center, Cedric Ghevaert, 103606
Novel biological information, novel therapeutic opportunities
EHA Learning Center, Steven Horwitz, 103610
Myths and Facts on the Management of Iron Overload
EHA Learning Center, Antonis Kattamis, 103589
Molecular surveillance post-transplant
EHA Learning Center, Ulrike Bacher, 103625
Global epidemiology of hemoglobinopathies: New management challenges
EHA Learning Center, Fred Piel, 103588
The role of glycosylation in the pathogenesis of alloimmune diseases
EHA Learning Center, Gestur Vidarsson, 103605
Dissecting the subclonal architecture and evolution in MM
EHA Learning Center, Dirk Hose, 103592
Mechanism of neonatal alloimmune diseases
EHA Learning Center, Anne Husebekk, 103604
Diagnostic challenges in T cell lymphomas
EHA Learning Center, Stefania Pittaluga, 103608
MRD response assessment and implications for clinical decision making
EHA Learning Center, Bruno Paiva, 103593
Epidemiology and risk factors for relapse in AML
EHA Learning Center, Gert Ossenkoppele, 103624
Cell and drug based prevention of relapse
EHA Learning Center, Alessandro Rambaldi, 103626
Emerging and established molecular markers
EHA Learning Center, Laurence de Leval, 103609
Bone marrow failure & Fanconi anemia
EHA Learning Center, Alan D'Andrea, 55641
AML: New therapeutic targets
EHA Learning Center, Scott Armstrong, 55642
CLL genomics
EHA Learning Center, Elias Campo, 55643
EHA19 Chair comments: The Future of Hematological Research in Europe
EHA Learning Center, Ulrich Jäger, 55634
The Roadmap for Research in Hematology in Europe
EHA Learning Center, Andreas Engert, 55635
The Perspective from Personalized Medicine
EHA Learning Center, Mark Lawler, 55636
The Perspective from Horizon 2020
EHA Learning Center, Hele Everaus, 55637
EHA19 Presidential Symposium - Best Abstracts: Introduction
EHA Learning Center, Pieter Sonneveld, 55626
EHA19 Jean Bernard Lifetime Achievement Award
EHA Learning Center, Freda Stevenson, 55627
A single oncogenic Enhancer-Rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
EHA Learning Center, Stefan Gröschel, 55628
Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia: results of a prospective phase II clinical trail
EHA Learning Center, Rosangela Invernizzi, 55629
Randomized comparision of Ibrutinib versus Ofatumumab in previously treated chronic Lymphocytic Leukemia / Small Lymphocytic lymphoma: Results from the phase III PCYC-1112 Resonate (TM) Trial
EHA Learning Center, Peter Hillmen, 55630
The KRÜPEL-Like factor 2 (KLF-2) Transcription factor is recurrently mutated in splenic marginal zone Lymphoma
EHA Learning Center, Davide Rossi, 55631
EHA19 Jean Bernard Lifetime Achievement Award: Introduction
EHA Learning Center, Christine Chomienne, 55625
EHA19 EHA-ASH Joint Symposium: Access to Medicines and Fair Pricing: the Cost of Innovative Drugs
EHA Learning Center, Jean-Luc Harousseau, 55623

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings